Comparative in vitro effectiveness of ceftolozane/tazobactam against pediatric gram-negative drug-resistant isolates

References

• Fair RJ, Tor Y. Antibiotics and Bacterial Resistance in the 21st Century. Perspect Med Chem. 2014;6:25–64.
   PubMedGoogle Scholar
• Platell JL, Johnson JR, Cobbold RN, Trott DJ. Multidrug-resistant extraintestinal pathogenic Escherichia coli of sequence type ST131 in animals and foods. Vet Microbiol. 2011;153(1-2):99–108.
   PubMed Web of Science ®Google Scholar
• CDC. Antibiotic/Antimicrobial Resistance Centers for Disease Control and Prevention. 2018. [Available from: https://www.cdc.gov/drugresistance/.
   Google Scholar
• Burnham J-O, Olsen MA, Kollef MH. Re-estimating annual deaths due to multidrug-resistant organism infections. Infect Control Hosp Epidemiol. 2019;40(1):112–3.
   PubMed Web of Science ®Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
   PubMed Web of Science ®Google Scholar
• Rawat D, Nair D. Extended-spectrum β-lactamases in Gram Negative Bacteria. J Glob Infect Dis. 2010;2(3):263–74.
   PubMedGoogle Scholar
• Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol. 2010;31(S1):S7–S10.
   PubMedGoogle Scholar
• Campfield B, Chen K, Kolls JK. Vaccine Approaches for Multidrug Resistant Gram negative infections. Curr Opin Immunol. 2014;28:84–9.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Bassetti M, De Rosa FG, Del Bono V, Grossi PA, Menichetti F, Pea F, Rossolini GM, Tumbarello M, Viale P, ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva), et al. Ceftolozane/tazobactam: place in therapy. Expert Rev anti Infect Ther. 2018;16(4):307–20.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43(6):533–9.
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes. Antimicrob Agents Chemother. 2011;55(5):2390–4.
   PubMed Web of Science ®Google Scholar
• Titelman E, Karlsson IM, Ge Y, Giske CG. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2011;70(1):137–41.
   PubMed Web of Science ®Google Scholar
• Sorbera M, Chung E, Ho CW, Marzella N. Ceftolozane/Tazobactam: A New Option in the Treatment of Complicated Gram-Negative Infections. P T. 2014;39(12):825–32.
   PubMedGoogle Scholar
• van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016;63(2):234–41.
   PubMed Web of Science ®Google Scholar
• Katchanov J, Asar L, Klupp E-M, Both A, Rothe C, König C, Rohde H, Kluge S, Maurer FP. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations. PLoS One. 2018;13(4):e0195757
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, Chaudhry A, Pike R, Staves P, Woodford N, BSAC Resistance Surveillance Standing Committee, et al. Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother. 2017;72(8):2278–89.
   PubMed Web of Science ®Google Scholar
• Meropol SB, Haupt AA, Debanne SM. Incidence and Outcomes of Infections Caused by Multidrug-Resistant Enterobacteriaceae in Children, 2007–2015. Journal of the Pediatric Infectious Diseases Society. 2018;7(1):36–45.
   PubMed Web of Science ®Google Scholar
• Murray TS, Peaper DR. The contribution of extended-spectrum β-lactamases to multidrug-resistant infections in children. Curr Opin Pediatr. 2015;27(1):124–31.
   PubMed Web of Science ®Google Scholar
• Zerr DM, Weissman SJ, Zhou C, Kronman MP, Adler AL, Berry JE, Rayar J, Myers J, Haaland WL, Burnham C-AD, et al. The Molecular and Clinical Epidemiology of Extended-Spectrum Cephalosporin- and Carbapenem-Resistant Enterobacteriaceae at 4 US Pediatric Hospitals. Journal of the Pediatric Infectious Diseases Society. 2017;6(4):366–75. 24(:
   PubMed Web of Science ®Google Scholar
• Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla M-F, Nusair A, Mirza I, et al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Int J Infect Dis. 2017;62:39–43.
   PubMed Web of Science ®Google Scholar
• Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. Microb Drug Resist. 2018;24(5):563–77.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother. 2014;69(10):2713–22.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother. 2013;57(12):6305–10.
   PubMed Web of Science ®Google Scholar
• Melchers MJB, van Mil A, Mouton JW. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae. Antimicrob Agents Chemother. 2015;59(8):4521–5.
   PubMed Web of Science ®Google Scholar